Business● Low34m ago · Nov 13, 2026, 12:20 AM
Biostem outlines $10M-$12M annual cash opex cuts as it targets in-house manufacturing in H1 2027
GlobeAlert Desk · curated from Seeking Alpha Tech · global
Biostem has announced plans to cut annual cash operating expenses by $10 million to $12 million. The company aims to achieve in-house manufacturing by the first half of 2027.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text. How we score stories.
GlobeAlert context
What the desk knows about this story
Threat level
0 Low
Scored from severity, scale, escalation potential and source agreement. Below the alert threshold.
Sources
1 publisher
Single-source so far. Treat details as unconfirmed until more publishers report.
Category
Business
Not flagged as developing.
More in Business
Business22m agoCruise ship detained by Coast Guard in Miami cleared to sailCBS NewsBusiness24m agoGCT Semiconductor anticipates 5G shipment ramp into first half of 2027 amid 150,000-unit 4G orderSeeking Alpha TechBusiness33m agoPrediction platform Kalshi fired Donald Trump Jr: Polymarket's role in his departure and why the timing is perfectClarínBusiness36m agoWith inflation, it's always five to the pesoClarín